Tissue and serum expression of TGM-3 may be prognostic marker in patients of oral squamous cell carcinoma undergoing chemo-radiotherapy.
Radioresistance is one of the main determinants of treatment outcome in oral squamous cell carcinoma (OSCC), but its prediction is difficult. Several authors aimed to establish radioresistant OSCC cell lines to identify genes with altered expression in response to radioresistance. The development of...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC6023195?pdf=render |
| _version_ | 1828347868861169664 |
|---|---|
| author | Seema Nayak M L B Bhatt Madhu Mati Goel Seema Gupta Abbas Ali Mahdi Anupam Mishra Divya Mehrotra |
| author_facet | Seema Nayak M L B Bhatt Madhu Mati Goel Seema Gupta Abbas Ali Mahdi Anupam Mishra Divya Mehrotra |
| author_sort | Seema Nayak |
| collection | DOAJ |
| description | Radioresistance is one of the main determinants of treatment outcome in oral squamous cell carcinoma (OSCC), but its prediction is difficult. Several authors aimed to establish radioresistant OSCC cell lines to identify genes with altered expression in response to radioresistance. The development of OSCC is a multistep carcinogenic process that includes activation of several oncogenes and inactivation of tumour suppressor genes. TGM-3 is a tumour suppressor gene and contributes to carcinogenesis process. The aim of this study was to estimate serum and tissue expression of TGM-3 and its correlation with clinico-pathological factors and overall survival in patients of OSCC undergoing chemo-radiotherapy. Tissue expression was observed in formalin fixed tissue biopsies of 96 cases of OSCC and 32 healthy controls were subjected to immunohistochemistry (IHC) by using antibody against TGM-3 and serum level was estimated by ELISA method. mRNA expression was determined by using Real-Time PCR. Patients were followed for 2 year for chemo radiotherapy response. In OSCC, 76.70% cases and in controls 90.62% were positive for TGM-3 IHC expression. TGM-3 expression was cytoplasmic and nuclear staining expressed in keratinized layer, stratum granulosum and stratum spinosum in controls and tumour cells. Mean serum TGM-3 in pre chemo-radiotherapy OSCC cases were 1304.83±573.55, post chemo-radiotherapy samples were 1530.64±669.33 and controls were 1869.16±1377.36, but difference was significant in pre chemo-radiotherapy samples as compared to controls (p<0.018). This finding was also confirmed by real- time PCR analysis in which down regulation (-7.92 fold change) of TGM-3 in OSCC as compared to controls. TGM-3 expression was significantly associated with response to chemo-radiotherapy treatment (p<0.007) and overall survival (p<0.015). Patents having higher level of TGM-3 expression have good response to chemo-radiotherapy and also have better overall survival. TGM-3 may serve as a candidate biomarker for responsiveness to chemo-radiotherapy treatment in OSCC patients. |
| first_indexed | 2024-04-14T00:46:32Z |
| format | Article |
| id | doaj.art-d8f80e5846184e5783db3fa9ed1d68bd |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-14T00:46:32Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-d8f80e5846184e5783db3fa9ed1d68bd2022-12-22T02:22:00ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01136e019966510.1371/journal.pone.0199665Tissue and serum expression of TGM-3 may be prognostic marker in patients of oral squamous cell carcinoma undergoing chemo-radiotherapy.Seema NayakM L B BhattMadhu Mati GoelSeema GuptaAbbas Ali MahdiAnupam MishraDivya MehrotraRadioresistance is one of the main determinants of treatment outcome in oral squamous cell carcinoma (OSCC), but its prediction is difficult. Several authors aimed to establish radioresistant OSCC cell lines to identify genes with altered expression in response to radioresistance. The development of OSCC is a multistep carcinogenic process that includes activation of several oncogenes and inactivation of tumour suppressor genes. TGM-3 is a tumour suppressor gene and contributes to carcinogenesis process. The aim of this study was to estimate serum and tissue expression of TGM-3 and its correlation with clinico-pathological factors and overall survival in patients of OSCC undergoing chemo-radiotherapy. Tissue expression was observed in formalin fixed tissue biopsies of 96 cases of OSCC and 32 healthy controls were subjected to immunohistochemistry (IHC) by using antibody against TGM-3 and serum level was estimated by ELISA method. mRNA expression was determined by using Real-Time PCR. Patients were followed for 2 year for chemo radiotherapy response. In OSCC, 76.70% cases and in controls 90.62% were positive for TGM-3 IHC expression. TGM-3 expression was cytoplasmic and nuclear staining expressed in keratinized layer, stratum granulosum and stratum spinosum in controls and tumour cells. Mean serum TGM-3 in pre chemo-radiotherapy OSCC cases were 1304.83±573.55, post chemo-radiotherapy samples were 1530.64±669.33 and controls were 1869.16±1377.36, but difference was significant in pre chemo-radiotherapy samples as compared to controls (p<0.018). This finding was also confirmed by real- time PCR analysis in which down regulation (-7.92 fold change) of TGM-3 in OSCC as compared to controls. TGM-3 expression was significantly associated with response to chemo-radiotherapy treatment (p<0.007) and overall survival (p<0.015). Patents having higher level of TGM-3 expression have good response to chemo-radiotherapy and also have better overall survival. TGM-3 may serve as a candidate biomarker for responsiveness to chemo-radiotherapy treatment in OSCC patients.http://europepmc.org/articles/PMC6023195?pdf=render |
| spellingShingle | Seema Nayak M L B Bhatt Madhu Mati Goel Seema Gupta Abbas Ali Mahdi Anupam Mishra Divya Mehrotra Tissue and serum expression of TGM-3 may be prognostic marker in patients of oral squamous cell carcinoma undergoing chemo-radiotherapy. PLoS ONE |
| title | Tissue and serum expression of TGM-3 may be prognostic marker in patients of oral squamous cell carcinoma undergoing chemo-radiotherapy. |
| title_full | Tissue and serum expression of TGM-3 may be prognostic marker in patients of oral squamous cell carcinoma undergoing chemo-radiotherapy. |
| title_fullStr | Tissue and serum expression of TGM-3 may be prognostic marker in patients of oral squamous cell carcinoma undergoing chemo-radiotherapy. |
| title_full_unstemmed | Tissue and serum expression of TGM-3 may be prognostic marker in patients of oral squamous cell carcinoma undergoing chemo-radiotherapy. |
| title_short | Tissue and serum expression of TGM-3 may be prognostic marker in patients of oral squamous cell carcinoma undergoing chemo-radiotherapy. |
| title_sort | tissue and serum expression of tgm 3 may be prognostic marker in patients of oral squamous cell carcinoma undergoing chemo radiotherapy |
| url | http://europepmc.org/articles/PMC6023195?pdf=render |
| work_keys_str_mv | AT seemanayak tissueandserumexpressionoftgm3maybeprognosticmarkerinpatientsoforalsquamouscellcarcinomaundergoingchemoradiotherapy AT mlbbhatt tissueandserumexpressionoftgm3maybeprognosticmarkerinpatientsoforalsquamouscellcarcinomaundergoingchemoradiotherapy AT madhumatigoel tissueandserumexpressionoftgm3maybeprognosticmarkerinpatientsoforalsquamouscellcarcinomaundergoingchemoradiotherapy AT seemagupta tissueandserumexpressionoftgm3maybeprognosticmarkerinpatientsoforalsquamouscellcarcinomaundergoingchemoradiotherapy AT abbasalimahdi tissueandserumexpressionoftgm3maybeprognosticmarkerinpatientsoforalsquamouscellcarcinomaundergoingchemoradiotherapy AT anupammishra tissueandserumexpressionoftgm3maybeprognosticmarkerinpatientsoforalsquamouscellcarcinomaundergoingchemoradiotherapy AT divyamehrotra tissueandserumexpressionoftgm3maybeprognosticmarkerinpatientsoforalsquamouscellcarcinomaundergoingchemoradiotherapy |